Ozempic and other weight-loss drugs linked to sudden vision loss risk, studies suggest

Once promoted as “miracle” slimming injections, certain diabetes medicines now used for weight loss are being examined anew by eye specialists.

As injectable weight-loss options soar in use, two sizeable studies are prompting uneasy discussion about an uncommon yet potentially devastating adverse effect: sudden loss of vision that can, in some cases, be permanent.

Ozempic and semaglutide: from type 2 diabetes treatment to weight-loss phenomenon

Ozempic, Wegovy and Rybelsus were created for medical care rather than cosmetic goals. They are semaglutide-based medicines, first authorised to help people with type 2 diabetes manage their blood glucose levels.

These treatments imitate a gut hormone known as GLP-1. GLP-1 signals the pancreas to produce insulin, slows the rate of digestion and triggers strong feelings of fullness in the brain, meaning many patients feel satisfied more quickly and for longer.

For a great many people, this leads to substantial weight reduction alongside improved blood pressure, cholesterol and blood sugar control. In people living with obesity or diabetes, those changes can mean fewer heart attacks and strokes, plus a longer and healthier life.

Online culture then reshaped that clinical narrative. “Ozempic face” and “skinny jabs” became regular features on TikTok and Instagram, and demand rose sharply among people who were not necessarily at high risk, or even significantly overweight.

"Behind the hype, researchers began to notice a faint but worrying pattern in the eye clinic waiting rooms."

What the latest eye studies are actually reporting

A rare diagnosis with a frightening nickname

The principal worry focuses on a condition with a long name: non-arteritic anterior ischaemic optic neuropathy (NAION). Ophthalmologists sometimes refer to it as a “stroke of the eye”.

NAION develops when circulation to the optic nerve - the “cable” carrying visual signals from the eye to the brain - drops abruptly. With too little oxygen, the nerve fibres can be damaged very quickly.

Most commonly, people wake to sudden, painless loss of sight in one eye. They might notice a dark area, patchy blur or a shadow across part of their field of vision. Often, the harm does not improve.

Although NAION is uncommon - only a few cases per 100,000 people each year - that very rarity means any uptick can stand out during drug-safety surveillance.

The Massachusetts study: semaglutide linked with a higher observed risk

One widely discussed investigation came from Massachusetts Eye and Ear Hospital. From 2017 to 2023, researchers tracked more than 16,000 patients who had diabetes or obesity.

They compared people prescribed semaglutide with those receiving other therapies, then counted how many individuals developed NAION during follow-up.

"The team found that NAION appeared more often in those using semaglutide: roughly four times higher risk in people with diabetes, and more than seven times higher in people with obesity."

This finding does not establish that semaglutide itself triggers NAION. Patients taking semaglutide may differ in important ways - including severity of illness and lifestyle - from those using other treatments. Even so, the scale of the dataset and the apparent strength of the association concerned both specialists and regulators.

Swedish and Australian evidence points the same way

In a separate analysis, scientists from the Karolinska Institutet in Sweden and the University of Melbourne examined a large population using GLP-1 medicines, semaglutide included.

They reported that NAION was still extremely uncommon, occurring in about 0.04% of treated patients. However, when compared with similar people not taking these drugs, the risk appeared slightly elevated.

A key difficulty is that diabetes alone increases NAION risk. A 2013 meta-analysis in PLOS ONE found a 64% higher risk of NAION among people with diabetes, even without weight-loss injections.

That makes it challenging to separate the contribution of the disease from any possible effect of the medicine. Rapid alterations in blood sugar associated with treatment may matter for susceptible individuals, but the biological mechanism remains unclear.

Regulators respond as clinicians weigh benefits against harms

Action has already been taken in Europe. In June 2025, the European Medicines Agency added NAION to the official list of “very rare” adverse effects for semaglutide, and advised patients to stop treatment immediately if they experience sudden changes in vision.

"Safety sheets now stress: any abrupt loss of vision, even in one eye and without pain, is an emergency that should halt injections until checked."

This puts doctors and patients in a familiar medical trade-off. Semaglutide can reduce cardiovascular risk, improve diabetes control and support significant - sometimes life-altering - weight loss. Set against that is a very uncommon but potentially severe threat to sight.

Who may be at higher risk?

Eye specialists note several features that may increase the likelihood of NAION:

• Obstructive sleep apnoea
  
• High blood pressure
  
• Diabetes with long-standing vascular damage
  
• Prior eye problems or previous NAION in the other eye
  
• Optic nerve structure that is less favourable, sometimes described as a “crowded” optic disc
  
• Smoking and high cholesterol
  

People with these characteristics often already have weakened microcirculation - the tiny vessels supplying the optic nerve and retina. The concern is that any medicine influencing blood flow, blood pressure or fluid balance could push a vulnerable system into crisis.

What people using Ozempic and similar medicines should look out for

For most individuals, abandoning a highly effective therapy because of a very rare side effect is unlikely to be the right answer. Instead, experts are urging more focused vigilance.

"Doctors now encourage patients on GLP-1 drugs to treat their eyes the way they treat their hearts: as organs needing monitoring when major metabolic changes are underway."

Clinicians commonly recommend practical measures such as:

• Arranging a baseline eye examination - including assessment of the optic nerve - before starting, or soon after beginning, a GLP-1 medicine.
  
• Informing your ophthalmologist or optometrist that you are using semaglutide (or a similar treatment).
  
• Getting urgent review if you wake with new blind spots, sudden blurring, or a dark “curtain” affecting part of your vision.
  
• Keeping up regular checks for blood pressure, cholesterol and sleep apnoea.
  

At the same time, longer-term studies are in progress. One ongoing project, tracking around 1,500 patients over five years, is designed to measure precisely how semaglutide influences the retina and optic nerve, and whether particular patterns can predict future problems.

Understanding how GLP-1 medicines might relate to eyesight

How GLP-1 treatment could affect the eye

Scientists are still mapping out possible reasons for an association between GLP-1 agonists and NAION. Several hypotheses are under discussion:

Suggested factor	Potential impact on the eye
Rapid blood sugar shifts	May briefly affect blood flow or pressure within the small vessels that nourish the optic nerve.
Changes in fluid balance	Weight loss and hormonal effects could alter pressure in and around the eye.
Pre-existing vascular injury	Diabetes-related damage to small vessels might magnify the effect of any added stress.
Personal anatomy	A naturally “crowded” optic disc may provide less room for swelling, increasing the chance of fibre injury.

None of these explanations has been definitively confirmed. The eye can be highly sensitive to subtle changes in circulation, and the mix of diabetes, obesity, sleep apnoea and potent metabolic medicines makes the picture complicated.

Real-world examples: when extra caution matters

Consider a middle-aged man with type 2 diabetes, high blood pressure and loud snoring that suggests sleep apnoea. He is prescribed Ozempic, and within months his weight and blood glucose improve. One morning he wakes to a blurred patch in his left eye, with no pain. He assumes it is tiredness and delays seeking help. By the time he reaches an eye clinic, the injury has stabilised and his vision cannot be recovered.

Now picture the same man, but properly briefed about potential eye risks. He has a baseline eye check, receives treatment for sleep apnoea, and understands that any sudden change in vision is urgent. At the first hint of a shadow, he pauses injections and seeks emergency assessment. The result may still be uncertain, but the opportunity for earlier action is far greater.

Balancing benefits, risks and longer-term planning

For people with severe obesity or diabetes that is difficult to control, semaglutide and related GLP-1 medicines can be genuinely transformative. Reducing strain on the heart and blood vessels typically supports eye health too, since diabetic eye disease is closely tied to overall vascular wellbeing.

The real issue is not simply whether these medicines should be used, but how to use them safely. That includes spotting patients with a vulnerable optic nerve, moderating the pace of weight loss when appropriate, and ensuring joined-up care between endocrinologists, GPs and eye specialists.

Anyone considering a GLP-1 medicine may wish to ask: “Do I have any diagnosed eye conditions?”, “Should I see an ophthalmologist before I start?”, and “Which warning signs mean I must stop injections and contact you?”. Clear, practical guidance on these points matters more than viral before-and-after images.

Ultimately, rapid weight loss brings physiological knock-on effects. Some are beneficial, such as lower blood pressure. Others - including a small rise in the risk of sudden vision loss - call for frank conversations, careful monitoring and informed decision-making by both clinician and patient.